29 results on '"Krämer, Alwin"'
Search Results
2. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
- Author
-
Niederwieser, Dietger, Lang, Thomas, Krahl, Rainer, Heinicke, Thomas, Maschmeyer, Georg, Al-Ali, Haifa Kathrin, Schwind, Sebastian, Jentzsch, Madlen, Cross, Michael, Kahl, Christoph, Wolf, Hans-Heinrich, Sayer, Herbert, Schulze, Antje, Dreger, Peter, Hegenbart, Ute, Krämer, Alwin, Junghanss, Christian, Mügge, Lars-Olof, Hähling, Detlev, Hirt, Carsten, Späth, Christian, Peter, Norma, Opitz, Bernhard, Florschütz, Axel, Reifenrath, Kolja, Zojer, Niklas, Scholl, Sebastian, Pönisch, Wolfram, Heyn, Simone, Vucinic, Vladan, Hochhaus, Andreas, Aul, Carlo, Giagounidis, Aristoteles, Balleisen, Leopold, Oldenkott, Bernd, Staib, Peter, Kiehl, Michael, Schütte, Wolfgang, Naumann, Ralph, Eimermacher, Hartmut, Dörken, Bernd, Sauerland, Cristina, Lengfelder, Eva, Hiddemann, Wolfgang, Wörmann, Bernhard, Müller-Tidow, Carsten, Serve, Hubert, Schliemann, Christoph, Hehlmann, Rüdiger, Berdel, Wolfgang E., Pfirrmann, Markus, Krug, Utz, and Hoffmann, Verena S.
- Published
- 2023
- Full Text
- View/download PDF
3. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
- Author
-
Kunadt, Desiree, Stasik, Sebastian, Metzeler, Klaus H., Röllig, Christoph, Schliemann, Christoph, Greif, Philipp A., Spiekermann, Karsten, Rothenberg-Thurley, Maja, Krug, Utz, Braess, Jan, Krämer, Alwin, Hochhaus, Andreas, Scholl, Sebastian, Hilgendorf, Inken, Brümmendorf, Tim H., Jost, Edgar, Steffen, Björn, Bug, Gesine, Einsele, Hermann, Görlich, Dennis, Sauerland, Cristina, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Wörmann, Bernhard, Kramer, Michael, Sockel, Katja, Egger-Heidrich, Katharina, Herold, Tobias, Ehninger, Gerhard, Burchert, Andreas, Platzbecker, Uwe, Berdel, Wolfgang E., Müller-Tidow, Carsten, Hiddemann, Wolfgang, Serve, Hubert, Stelljes, Matthias, Baldus, Claudia D., Neubauer, Andreas, Schetelig, Johannes, Thiede, Christian, Bornhäuser, Martin, Middeke, Jan M., and Stölzel, Friedrich
- Published
- 2022
- Full Text
- View/download PDF
4. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
- Author
-
Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Kroschinsky, Frank, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz
- Published
- 2022
- Full Text
- View/download PDF
5. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
- Author
-
Kang, Dongwoo, Ludwig, Elizabeth, Jaworowicz, David, Huang, Hannah, Fiedler-Kelly, Jill, Cortes, Jorge, Ganguly, Siddhartha, Khaled, Samer, Krämer, Alwin, Levis, Mark, Martinelli, Giovanni, Perl, Alexander, Russell, Nigel, Abutarif, Malaz, Choi, Youngsook, and Yin, Ophelia
- Published
- 2021
- Full Text
- View/download PDF
6. Enasidenib
- Author
-
Krämer, Alwin, Bochtler, Tilmann, Schlag, Peter-Michael, Series Editor, Senn, Hans-Jörg, Series Editor, and Martens, Uwe M., editor
- Published
- 2018
- Full Text
- View/download PDF
7. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.
- Author
-
DiNardo, Courtney D., Hochhaus, Andreas, Frattini, Mark G., Yee, Karen, Zander, Thomas, Krämer, Alwin, Chen, Xueying, Ji, Yan, Parikh, Nehal S., Choi, Joanne, and Wei, Andrew H.
- Subjects
ACUTE myeloid leukemia ,MYELODYSPLASTIC syndromes ,ISOCITRATE dehydrogenase ,AMINO acid residues ,ASPARTATE aminotransferase ,GLUCOSE-6-phosphate dehydrogenase deficiency ,TUMOR lysis syndrome - Abstract
Purpose: Isocitrate dehydrogenase enzyme 1 (IDH1) mutations at 132nd amino acid residue (R132*) result in the cellular accumulation of the oncometabolite, 2-hydroxyglutarate (2-HG). IDH305 is an orally bioavailable, brain-penetrant, mutant-selective allosteric IDH1 inhibitor demonstrating target engagement in preclinical models. This first-in human study was designed to identify the recommended dose for expansion/maximum tolerated dose of IDH305 in patients with IDH1
R132 -mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: IDH305 was given at doses 75–750 mg twice daily in 41 patients with IDH1R132 -mutant AML/MDS. Dose escalation was designed using Bayesian hierarchical model with overdose control principle and relationship with dose-limiting toxicity. Results: IDH305 exhibited rapid absorption with mean T1/2 approximately 4–10 h across doses. Interpatient variability was moderate and exposure increased with dose in a less than dose proportional manner. Most patients (35/41) demonstrated target engagement with reduction in 2-HG concentration at all doses. Complete remission (CR) or CR with incomplete count recovery occurred in 10/37 (27%) patients with AML and 1/ 4 patients with MDS. Adverse events (AEs) suspected to be related to study drug were reported in 53.7% of patients: increased blood bilirubin (14.6%), nausea (14.6%), increased alanine aminotransferase and aspartate aminotransferase (12.2%, each); most frequent grade 3 or 4 AEs were differentiation syndrome and tumor lysis syndrome (n = 3; 7.3%, each). Hepatotoxicity was manageable with dose modification. Conclusion: Due to potentially narrow therapeutic window, the study was prematurely halted and recommended phase 2 dose could not be declared. Trial registration: Clinicaltrials.gov identifier: NCT02381886. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. Loss-of-function mutations of bcor are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia
- Author
-
Eckardt, Jan-Niklas, Stasik, Sebastian, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiří, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Stölzel, Friedrich, Kroschinsky, Frank, Schetelig, Johannes, Bornhäuser, Martin, Thiede, Christian, and Middeke, Jan Moritz
- Subjects
Medizin ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,risk stratification ,acute myeloid leukemia ,BCOR ,survival ,Article ,loss-of-function ,hemic and lymphatic diseases ,ddc:610 ,BCORL1 ,RC254-282 - Abstract
Cancers 13(9), 2095 (2021). doi:10.3390/cancers13092095, Published by MDPI, Basel
- Published
- 2021
9. Biologie und risikoadaptierte Therapie der akuten myeloischen Leukämie
- Author
-
Krämer, Alwin
- Published
- 2009
- Full Text
- View/download PDF
10. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes
- Author
-
Neben, Kai, Tews, Björn, Wrobel, Gunnar, Hahn, Meinhard, Kokocinski, Felix, Giesecke, Christian, Krause, Ulf, Ho, Anthony D, Krämer, Alwin, and Lichter, Peter
- Published
- 2004
- Full Text
- View/download PDF
11. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study
- Author
-
Kayser, Sabine, Hills, Robert K., Luskin, Marlise R., Brunner, Andrew M., Terré, Christine, Westermann, Jörg, Menghrajani, Kamal, Shaw, Carole, Baer, Maria R., Elliott, Michelle A., Perl, Alexander E., Ráčil, Zdeněk, Mayer, Jiri, Zak, Pavel, Szotkowski, Tomas, de Botton, Stéphane, Grimwade, David, Mayer, Karin, Walter, Roland B., Krämer, Alwin, Burnett, Alan K., Ho, Anthony D., Platzbecker, Uwe, Thiede, Christian, Ehninger, Gerhard, Stone, Richard M., Röllig, Christoph, Tallman, Martin S., Estey, Elihu H., Müller-Tidow, Carsten, Russell, Nigel H., Schlenk, Richard F., and Levis, Mark J.
- Subjects
Adult ,Acute Myeloid Leukemia ,Leukemia, Myeloid, Acute ,hemic and lymphatic diseases ,Remission Induction ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Humans ,Middle Aged ,Disease-Free Survival ,Article ,Retrospective Studies - Abstract
Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.
- Published
- 2019
12. Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.
- Author
-
Kang, Dongwoo, Ludwig, Elizabeth, Jaworowicz, David, Huang, Hannah, Fiedler‐Kelly, Jill, Cortes, Jorge, Ganguly, Siddhartha, Khaled, Samer, Krämer, Alwin, Levis, Mark, Martinelli, Giovanni, Perl, Alexander, Russell, Nigel, Abutarif, Malaz, Choi, Youngsook, Mendell, Jeanne, and Yin, Ophelia
- Subjects
BLACK people ,ORAL drug administration ,RACE ,PROTEIN-tyrosine kinase inhibitors ,BODY surface area ,ACUTE erythroid leukemia ,CYTOCHROME P-450 ,CHEMICAL inhibitors - Abstract
Quizartinib is an FMS‐like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3‐internal tandem duplication–mutated relapsed/refractory acute myeloid leukemia (AML). This analysis evaluated the population pharmacokinetics (PK) of quizartinib and its active metabolite, AC886, in a pooled analysis of data from 649 healthy volunteers or patients with AML from 8 clinical trials including the phase 3 QuANTUM‐R study. Quizartinib was given as a single dose or multiple once‐daily doses of 20, 30, 60, or 90 mg. Nonlinear mixed‐effects modeling was performed using observed concentrations of quizartinib and AC886. Strong CYP3A inhibitor use resulted in an 82% increase in the area under the curve (AUC) and a 72% increase in the maximum concentration (Cmax) of quizartinib. Albumin level, age, and body surface area were statistically significant covariates on quizartinib PK. However, their individual effects on quizartinib AUC and Cmax were <20%. For AC886, strong CYP3A inhibitor use, body surface area and black/African American race were significant covariates. Except for strong CYP3A inhibitor use, the effects on the overall exposure (AUC of quizartinib + AC886) were <20%. The population PK model provided an adequate description of the observed concentrations of quizartinib and AC886 in both healthy volunteers and patients with AML. Only concomitant use of strong CYP3A inhibitors had a clinically meaningful effect on quizartinib PK exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
- Author
-
Bixby, Dale, Fiedler, Walter, Dimier, Natalie, Simmons, Brian P., Riehl, Todd, Colburn, Dawn, Noppeney, Richard, Lin, Tara L., Cortes, Jorge, Krauter, Jürgen, Yee, Karen, Medeiros, Bruno C., Krämer, Alwin, and Assouline, Sarit
- Subjects
AZACITIDINE ,ACUTE myeloid leukemia ,VISMODEGIB - Abstract
The article focuses on the efficiency of the Hedgehog pathway inhibitor (HPI) Vismodegib in the treatment of patients experiencing a relapse of acute myeloid leukaemia (AML). It talks about the Hedgehog signalling being important in maintaining leukaemia stem cells (LSCs) in the patient's body. It tells about Vismodegib being able to bind Smoothened (SMO) in the body.
- Published
- 2019
- Full Text
- View/download PDF
14. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
- Author
-
Kayser, Sabine, Feszler, Maximilian, Krzykalla, Julia, Schick, Matthias, Kramer, Michael, Benner, Axel, Thol, Felicitas, Platzbecker, Uwe, Müller‐Tidow, Carsten, Ho, Anthony D., Ehninger, Gerhard, Heuser, Michael, Schlenk, Richard F., Thiede, Christian, Röllig, Christoph, and Krämer, Alwin
- Subjects
GENE expression ,TUMOR suppressor genes ,ACUTE myeloid leukemia ,CANCER patients ,HEMATOLOGIC malignancies - Abstract
Objective To evaluate the prognostic impact of gene expression levels ( ELs) of two tumor suppressor genes, sprouty 4 ( SPRY4, located on 5q) and lysine methyltransferase 2C ( KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia ( AML). Method Gene expression levels were measured on cDNA by RT- qPCR from diagnostic bone marrow samples of 275 intensively treated adult AML patients (median age, 48 years). Results KMT2C ELs were significantly lower in abn7q/-7 ( P = .001), whereas SPRY4 ELs were not associated with abn5q/-5. Higher KMT2C and SPRY4 ELs were significantly associated with lower genetic risk groups as defined by the European LeukemiaNet classification. Additionally, KMT2C ELs were lower in cytogenetically normal patients with DNMT3A ( P = .01) or FLT3- ITD mutations ( P = .05). KMT2C ELs were not associated with prognosis, whereas higher SPRY4 ELs showed a favorable impact on event-free ( EFS, P = .01), relapse-free ( RFS, P = .01) and in-trend on overall survival ( P = .06) for cytogenetically abnormal patients, which was confirmed in multivariable analysis for EFS ( HR, 0.84; 95%- CI, 0.73-0.97; P = .02) and RFS ( HR, 0.85; 95%- CI, 0.73-0.98; P = .02). Conclusion Our data indicate that KMT2C ELs are associated with specific genetic features and that SPRY4 ELs may add prognostic information. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience.
- Author
-
Radujkovic, Aleksandar, Dietrich, Sascha, Bochtler, Tilmann, Krämer, Alwin, Schöning, Tilman, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Subjects
ACUTE myeloid leukemia ,AZACITIDINE ,CYTARABINE ,BONE marrow ,FEBRILE neutropenia ,MULTIVARIATE analysis ,PATIENTS ,THERAPEUTICS - Abstract
We retrospectively analyzed and compared the efficacy and toxicity of azacitidine ( AZA) and low-dose cytarabine ( LD- Ara- C) in 65 palliative patients with acute myeloid leukemia ( AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD- Ara- C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD- Ara- C group. AZA and LD- Ara- C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD- Ara- C groups, respectively, without statistically significant difference. In multivariate analysis ( n = 65), previous treatment ( HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics ( HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
- Author
-
Müller‐Tidow, Carsten, Bug, Gesine, Lübbert, Michael, Krämer, Alwin, Krauter, Jürgen, Valent, Peter, Nachbaur, David, Berdel, Wolfgang E., Ottmann, Oliver G., Fritsch, Holger, Munzert, Gerd, Garin‐Chesa, Pilar, Fleischer, Frank, Taube, Tillmann, and Döhner, Hartmut
- Subjects
POLO-like kinases ,SERINE/THREONINE kinases ,DISEASES in older people ,ACUTE myeloid leukemia ,ACUTE leukemia - Abstract
Polo-like kinases (Plks) play an important role in cell cycle checkpoint controls and are over-expressed in acute myeloid leukaemia ( AML). BI 2536, a novel Plk inhibitor, induces mitotic arrest and apoptosis. In this phase I/II trial of BI 2536 in 68 elderly patients with relapsed/refractory AML, three schedules were investigated (day 1, days 1-3, and days 1 + 8). Maximum tolerated dose was 350 and 200 mg in the day 1 and days 1 + 8 schedules, respectively. The day 1-3 schedule appeared equivalent to the day 1 schedule and was discontinued early. BI 2536 exhibited multi-compartmental pharmacokinetic behaviour. The majority of patients showed an increase of bone marrow cells in G2/M with a characteristic pattern of mitotic catastrophe. The overall response rate in the day 1 and day 1 + 8 schedules was 9% (5/54) with 2 complete and 3 partial responses. The majority of drug-related adverse events grade ≥3 were haematological. Taken together, Plk inhibition induced cell cycle arrest in AML blasts in vivo and BI 2536 monotherapy showed modest clinical activity in this poor prognosis patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. EVI1 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells.
- Author
-
Rommer, Anna, Steinmetz, Birgit, Herbst, Friederike, Hackl, Hubert, Heffeter, Petra, Heilos, Daniela, Filipits, Martin, Steinleitner, Katarina, Hemmati, Shayda, Herbacek, Irene, Schwarzinger, Ilse, Hartl, Katharina, Rondou, Pieter, Glimm, Hanno, Karakaya, Kadin, Krämer, Alwin, Berger, Walter, and Wieser, Rotraud
- Subjects
MYELOID leukemia ,LEUKEMIA treatment ,APOPTOSIS ,ANTINEOPLASTIC agents ,CELL lines ,ANTIRETROVIRAL agents ,DAUNOMYCIN ,GENE expression ,VIRAL integration (Genetics) ,CANCER chemotherapy - Abstract
Overexpression of ecotropic viral integration site 1 (EVI1) is associated with aggressive disease in acute myeloid leukemia (AML). Despite of its clinical importance, little is known about the mechanism through which EVI1 confers resistance to antileukemic drugs. Here, we show that a human myeloid cell line constitutively overexpressing EVI1 after infection with a retroviral vector (U937_EVI1) was partially resistant to etoposide and daunorubicin as compared to empty vector infected control cells (U937_vec). Similarly, inducible expression of EVI1 in HL-60 cells decreased their sensitivity to daunorubicin. Gene expression microarray analyses of U937_EVI1 and U937_vec cells cultured in the absence or presence of etoposide showed that 77 and 419 genes were regulated by EVI1 and etoposide, respectively. Notably, mRNA levels of 26 of these genes were altered by both stimuli, indicating that EVI1 regulated genes were strongly enriched among etoposide regulated genes and vice versa. One of the genes that were induced by both EVI1 and etoposide was CDKN1A/p21/WAF, which in addition to its function as a cell cycle regulator plays an important role in conferring chemotherapy resistance in various tumor types. Indeed, overexpression of CDKN1A in U937 cells mimicked the phenotype of EVI1 overexpression, similarly conferring partial resistance to antileukemic drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
- Author
-
Röllig, Christoph, Brandts, Christian, Shaid, Shabnam, Hentrich, Marcus, Krämer, Alwin, Junghanß, Christian, Schleyer, Eberhard, Müller-Tidow, Carsten, Berdel, Wolfgang E., Ritter, Barbara, Pflüger, Karl-Heinz, Kramer, Michael, Haibach, Martina, Ehninger, Gerhard, Serve, Hubert, and Krause, Stefan W.
- Subjects
DRUG efficacy ,DRUG prescribing ,ACUTE myeloid leukemia ,CARCINOGENESIS ,GRAM-negative bacteria ,PATIENTS - Abstract
Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. However, clinical data are still sparse, and there are only a few reported cases of monotherapy. The aim of the present research was to collect clinical data on efficacy and safety in a systematic way by conducting a survey on clinical experience with sorafenib. Thirty institutions were asked to document all patients treated with sorafenib diagnosed with AML. Of all 29 evaluable patients, six (21%) responded to sorafenib containing treatment by achieving a complete remission (CR, n = 2) or complete remission with incomplete platelet recovery (CRi, n = 4). In 23 patients receiving sorafenib as monotherapy, the CRi rate amounted to 13% and no CRs were documented. Of the 18 FLT-ITD positive patients with sorafenib monotherapy, two patients achieved a CRi (11%). In five FLT3-ITD negative cases, one CRi was documented (20%). Our results suggest the potential ability of the drug to induce remissions in refractory or relapsed AML even when given as monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Antiapoptotic function of charged multivesicular body protein 5: A potentially relevant gene in acute myeloid leukemia.
- Author
-
Shahmoradgoli, Maria, Mannherz, Otto, Engel, Felix, Heck, Stefanie, Krämer, Alwin, Seiffert, Martina, Pscherer, Armin, and Lichter, Peter
- Subjects
PROTEIN research ,ACUTE myeloid leukemia ,ACUTE leukemia ,RNA ,RIBOSE - Abstract
The article discusses a study on the role of charged multivesicular body protein 5 (CHMP5) in acute myeloid leukemia (AML). A short-hairpin ribonucleic acid (RNA)-based RNA interference (RNAi) screening of functionally uncharacterized human genes was performed to determine whether the genes can inhibit apoptosis. A new antiapoptotic function for charged multivesicular body protein 5 (CHMP5) was identified. CHMP5 silencing was found to induce caspase cascade activation by means of extrinsic apoptosis pathway.
- Published
- 2011
- Full Text
- View/download PDF
20. Centrosome aberrations in hematological malignancies
- Author
-
Krämer, Alwin, Neben, Kai, and Ho, Anthony D.
- Subjects
- *
CENTROSOMES , *DNA replication , *DNA synthesis , *HEMATOLOGY - Abstract
Abstract: As the primary microtubule organizing center of most eukaryotic cells, centrosomes play a fundamental role in proper formation of the mitotic spindle and subsequent chromosome separation. Normally, the single centrosome of a G1 cell duplicates precisely once prior to mitosis in a process that is intimately linked to the cell division cycle via cyclin-dependent kinase (cdk) 2 activity that couples centrosome duplication to the onset of DNA replication at the G1/S transition. Accurate control of centrosome duplication is critical for symmetric mitotic spindle formation and thereby contributes to the maintenance of genome integrity. Numerical and structural centrosome abnormalities are hallmarks of almost all solid tumors and have been implicated in the generation of multipolar mitoses and chromosomal instability. In addition to solid neoplasias, centrosome aberrations have recently been described in several different hematological malignancies like acute myeloid leukemias, myelodysplastic syndromes, Hodgkin''s as well as non-Hodgkin''s lymphomas, chronic lymphocytic leukemias and multiple myelomas. In analogy to many solid tumors a correlation between centrosome abnormalities on the one hand and karyotype aberrations as well as clinical aggressiveness on the other hand seems to exist in myeloid malignancies, chronic lymphocytic leukemias and at least some types of non-Hodgkin''s lymphomas. Molecular mechanisms responsible for the development of centrosome aberrations are just beginning to be unraveled. In general, two models with distinct functional consequences can be envisioned. First, centrosome aberrations can arise as a consequence of abortive mitotic events and impaired cytokinesis. Second, evidence has been provided that centrosome amplification can also precede genomic instability and arise in normal, diploid cells. Accordingly, this review will focus on recent advances in the understanding of both, causes and consequences of centrosome aberrations in hematological malignancies. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
21. Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations Letter to the Editor.
- Author
-
Sellner, Leopold, Capper, David, Meyer, Jochen, Langhans, Claus-Dieter, Hartog, Christine-Maria, Pfeifer, Heike, Serve, Hubert, Ho, Anthony D., Okun, Jürgen G., Krämer, Alwin, and Von Deimling, Andreas
- Subjects
LETTERS to the editor ,ACUTE myeloid leukemia ,PATIENTS - Abstract
A letter to the editor is presented about the increase in 2-hydroxyglutarate in patients with acute myeloid leukemia (AML), a clonal malignancy of myeloid blood progenitor cells.
- Published
- 2010
- Full Text
- View/download PDF
22. The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia.
- Author
-
Yu, Weijia, Lutz, Christoph, Krämer, Alwin, and Schmidt-Zachmann, Marion S.
- Subjects
- *
ACUTE myeloid leukemia , *CELLULAR control mechanisms , *GENETIC regulation , *CELL populations , *ORGANELLE formation - Abstract
As epigenetic regulators are frequently dysregulated in acute myeloid leukemia (AML) we determined expression levels of the JmjC-protein NO66 in AML cell lines and sub fractions of healthy human hematopoietic cells. NO66 is absent in the AML cell lines KG1/KG1a which consist of cells with the immature CD34+/CD38- phenotype and is regarded as a "stem cell-like" model system. Similarly, NO66 is not detectable in CD34+/CD38- cells purified from healthy donors but is clearly expressed in the more committed CD34+/CD38+ cell population. Loss of NO66 expression in KG1/KG1a cells is due to hyper-methylation of its promoter and is released by DNA-methyltransferase inhibitors. In KG1a cells stably expressing exogenous wild type (KG1a66wt) or enzymatically inactive mutant (KG1a66mut) NO66, respectively, the wild type protein inhibited proliferation and rDNA transcription. Gene expression profiling revealed that the expression of NO66 induces a transcriptional program enriched for genes with roles in proliferation and maturation (e.g.EPDR1, FCER1A, CD247, MYCN, SNORD13). Genes important for the maintenance of stem cell properties are downregulated (e.g. SIRPA, Lin28B, JAML). Our results indicate that NO66 induces lineage commitment towards myeloid progenitor cell fate and suggest that NO66 contributes to loss of stem cell properties. • NO66/RIOX1 is not expressed in the AML cell line KG1a regarded as a "stem cell-like" model system. • NO66/RIOX1 is not expressed in primary HSC-enriched CD34+/CD38- cells of healthy donors. • Ectopic expression of NO66/RIOX1 in KG1a cells inhibits proliferation and rDNA transcription. • NO66/RIOX1 impacts on the transition from stem cells to progenitors by regulation of gene expression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
- Author
-
Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., and Khaled, Samer K.
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *CANCER chemotherapy - Abstract
In QuANTUM-R, the once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefit vs SC (median overall survival [mOS], 6.2 vs 4.7 mo [HR, 0.76 (95% CI, 0.58-0.98); P =.02]) in R/R FLT3 -ITD AML (NCT02039726). Before randomization, 25% (Q) and 23% (SC) of pts had 1 prior HSCT. To describe post hoc analyses in pts who underwent subsequent HSCT during QuANTUM-R. Pts with FLT3 -ITD R/R AML received Q (60 mg [30-mg lead-in]) or SC. Pts in the Q arm could resume Q 30-100 d after HSCT. Decisions to proceed to HSCT and resume Q after HSCT were made per investigator discretion/institutional policy. Of 367 randomized pts, 85 in the Q arm underwent any subsequent HSCT (allogeneic HSCT [allo-HSCT], 84 [6 with and 78 w/o additional AML therapy]; autologous HSCT, 1), and 19 in the SC arm underwent any HSCT (5 with and 14 w/o additional AML therapy]). Q + SC pooled data showed a longer mOS (95% CI) in 104 pts with any HSCT vs 263 w/o (12.2 [10.0-24.1] vs 4.4 [4.1-4.9] mo; P <.0001; Fig 1); 1-year OS rates were 50% vs 13%. Among pts preselected for low-intensity therapy, 13/57 in the Q arm and 0/29 in the SC arm underwent any HSCT. Q + SC pooled data also showed a longer mOS (95% CI) in pts with a composite complete remission (CRc) as last recorded response before allo-HSCT vs pts w/o CRc (20.1 [11.7-NA] vs 8.8 [7.0-11.4] mo). Regardless of treatment, mOS was longer with any HSCT vs w/o (Q, 11.9 [10.2-25.1] vs 4.5 [4.1-5.4] mo; SC, 12.7 [6.1-NA] vs 4.0 [2.7-5.0] mo); respective 1-year OS rates were 50% vs 13% and 51% vs 12%. In the Q arm, mOS (95% CI) was longer in pts with a best response of CRc who resumed Q after allo-HSCT (27.1 [18.2-NA] mo) vs pts not resuming Q (5.4 [4.7-11.4] mo; Fig 2). In 48 pts (62%) in the Q arm resuming Q after allo-HSCT, median time from allo-HSCT to Q resumption was 65 d (range, 30-106 d). Four pts (5%) in the Q arm died < 30 d after allo-HSCT. As of 2/22/2018, 46/78 pts in the Q arm (59%) and 9/14 pts in the SC arm (64%) with allo-HSCT w/o additional AML therapy died, mostly due to AML progression (Q, 31 [40%]; SC, 7 [50%]). The frequency of treatment-emergent adverse events (TEAEs) and TEAEs of interest was similar in pts resuming Q after allo-HSCT and in the overall Q population. Independent of HSCT, Q improved survival vs SC in pts with FLT3 -ITD R/R AML in QuANTUM-R. Q + SC pooled analyses showed longer survival in pts with HSCT vs pts w/o and in pts with CRc before allo-HSCT. Survival in transplanted pts was similar in both arms, indicating that HSCT-eligible pts received transplants appropriately, and the higher HSCT rate in the Q arm was beneficial. In pts preselected for low-intensity SC at study entry, 13 were able to undergo HSCT after Q treatment. Q resumption after HSCT was associated with better survival outcomes and was tolerable. These data illustrate the value of using Q to target the FLT3 -ITD mutation as a part of the overall treatment sequence in pts with FLT3 -ITD R/R AML. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
- Author
-
Platzbecker, Uwe, Middeke, Jan Moritz, Sockel, Katja, Herbst, Regina, Wolf, Dominik, Baldus, Claudia D, Oelschlägel, Uta, Mütherig, Anke, Fransecky, Lars, Noppeney, Richard, Bug, Gesine, Götze, Katharina S, Krämer, Alwin, Bochtler, Tilmann, Stelljes, Matthias, Groth, Christoph, Schubert, Antje, Mende, Marika, Stölzel, Friedrich, and Borkmann, Christine
- Subjects
- *
MYELODYSPLASTIC syndromes , *CYCLOPHOSPHAMIDE , *AZACITIDINE , *LEUKEMIA , *CANCER chemotherapy , *CARCINOGENESIS , *ANTIMETABOLITES , *ANTINEOPLASTIC agents , *COMPARATIVE studies , *DRUG administration , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RISK assessment , *TIME , *DISEASE relapse , *EVALUATION research , *ACUTE myeloid leukemia - Abstract
Background: Monitoring of measurable residual disease (MRD) in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a morphological complete remission can predict haematological relapse. In this prospective study, we aimed to determine whether MRD-guided pre-emptive treatment with azacitidine could prevent relapse in these patients.Methods: The relapse prevention with azacitidine (RELAZA2) study is an open-label, multicentre, phase 2 trial done at nine university health centres in Germany. Patients aged 18 years or older with advanced MDS or AML, who had achieved a complete remission after conventional chemotherapy or allogeneic haemopoietic stem-cell transplantation, were prospectively screened for MRD during 24 months from baseline by either quantitative PCR for mutant NPM1, leukaemia-specific fusion genes (DEK-NUP214, RUNX1-RUNX1T1, CBFb-MYH11), or analysis of donor-chimaerism in flow cytometry-sorted CD34-positive cells in patients who received allogeneic haemopoietic stem-cell transplantation. MRD-positive patients in confirmed complete remission received azacitidine 75 mg/m2 per day subcutaneously on days 1-7 of a 29-day cycle for 24 cycles. After six cycles, MRD status was reassessed and patients with major responses (MRD negativity) were eligible for a treatment de-escalation. The primary endpoint was the proportion of patients who were relapse-free and alive 6 months after the start of pre-emptive treatment. Analyses were done per protocol. This trial is registered with ClincialTrials.gov, number NCT01462578, and finished recruitment on Aug 21, 2018.Findings: Between Oct 10, 2011, and Aug 20, 2015, we screened 198 patients with advanced MDS (n=26) or AML (n=172), of whom 60 (30%) developed MRD during the 24-month screening period and 53 (88%) were eligible to start study treatment. 6 months after initiation of azacitidine, 31 (58%, 95% CI 44-72) of 53 patients were relapse-free and alive (p<0·0001; one-sided binomial test for null hypothesis pexp≤0·3). With a median follow-up of 13 months (IQR 8·5-22·8) after the start of MRD-guided treatment, relapse-free survival at 12 months was 46% (95% CI 32-59) in the 53 patients who were MRD-positive and received azacitidine. In MRD-negative patients, 12-month relapse-free survival was 88% (95% CI 82-94; hazard ratio 6·6 [95% CI 3·7-11·8], p<0·0001). The most common (grade 3-4) adverse event was neutropenia, occurring in 45 (85%) of 53 patients. One patient with neutropenia died because of an infection considered possibly related to study treatment.Interpretation: Pre-emptive therapy with azacitidine can prevent or substantially delay haematological relapse in MRD-positive patients with MDS or AML who are at high risk of relapse. Our study also suggests that continuous MRD negativity during regular MRD monitoring might be prognostic for patient outcomes.Funding: Celgene Pharma, José Carreras Leukaemia Foundation, National Center for Tumor Diseases (NCT), and German Cancer Consortium (DKTK) Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
- Author
-
Cortes, Jorge, Perl, Alexander E, Döhner, Hartmut, Kantarjian, Hagop, Martinelli, Giovanni, Kovacsovics, Tibor, Rousselot, Philippe, Steffen, Björn, Dombret, Hervé, Estey, Elihu, Strickland, Stephen, Altman, Jessica K, Baldus, Claudia D, Burnett, Alan, Krämer, Alwin, Russell, Nigel, Shah, Neil P, Smith, Catherine C, Wang, Eunice S, and Ifrah, Norbert
- Subjects
- *
PROTEIN-tyrosine kinases , *ACUTE myeloid leukemia , *GENETIC mutation , *PLATELET count , *PNEUMONIA , *ACUTE myeloid leukemia diagnosis , *THIAZOLES , *UREA , *CANCER relapse , *CLINICAL trials , *COMPARATIVE studies , *DRUG administration , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *INTERNATIONAL relations , *RESEARCH methodology , *MEDICAL cooperation , *ORAL drug administration , *PROGNOSIS , *RESEARCH , *RESEARCH funding , *SURVIVAL , *TRANSFERASES , *EVALUATION research , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Background: Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia.Methods: We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed.Findings: Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [<1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died within the study treatment period, including the 30-day follow-up. 18 (5%) patients died because of an adverse event considered by the investigator to be treatment related (ten [6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2.Interpretation: Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses.Funding: Ambit Biosciences/Daiichi Sankyo. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.
- Author
-
Bochtler, Tilmann, Granzow, Martin, Stölzel, Friedrich, Kunz, Christina, Mohr, Brigitte, Kartal-Kaess, Mutlu, Hinderhofer, Katrin, Heilig, Christoph E., Kramer, Michael, Thiede, Christian, Endris, Volker, Kirchner, Martina, Stenzinger, Albrecht, Benner, Axel, Bornhäuser, Martin, Ehninger, Gerhard, Ho, Anthony D., Jauch, Anna, and Krämer, Alwin
- Subjects
- *
CHROMOTHRIPSIS , *ACUTE myeloid leukemia , *BIOMARKERS , *KARYOTYPES , *CYTOGENETICS , *PROGNOSIS - Abstract
Metaphase karyotyping is an established diagnostic standard in acute myeloid leukemia (AML) for risk stratification. One of the cytogenetic findings in AML is structurally highly abnormal marker chromosomes. In this study, we have assessed frequency, cytogenetic characteristics, prognostic impact, and underlying biological origin of marker chromosomes. Given their inherent gross structural chromosomal damage, we speculated that they may arise from chromothripsis, a recently described phenomenon of chromosome fragmentation in a single catastrophic event. In 2 large consecutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the Study Alliance Leukemia, marker chromosomes were detectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients. Adverse-risk karyotypes displayed a higher frequency of marker chromosomes (26.5% in adverse-risk, 40.3% in complex aberrant, and 41.2% in abnormality(17p) karyotypes, P < .0001 each). Marker chromosomes were associated with a poorer prognosis compared with other non-CBF aberrant karyotypes and led to lower remission rates (complete remission 1 complete remission with incomplete recovery), inferior event-free survival as well as overall survival in both trials. In multivariate analysis, marker chromosomes independently predicted poor prognosis in the AML96 trial ≤60 years. As detected by array comparative genomic hybridization, about one-third of marker chromosomes (18/49) had arisen from chromothripsis, whereas this phenomenon was virtually undetectable in a control group of marker chromosome-negative complex aberrant karyotypes (1/34). The chromothripsis-positive cases were characterized by a particularly high degree of karyotype complexity, TP53 mutations, and dismal prognosis. In conclusion, marker chromosomes are indicative of chromothripsis and associated with poor prognosis per se and not merely by association with other adverse cytogenetic features. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
- Author
-
Röllig, Christoph, Serve, Hubert, Hüttmann, Andreas, Noppeney, Richard, Müller-Tidow, Carsten, Krug, Utz, Baldus, Claudia D, Brandts, Christian H, Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W, Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, and Hänel, Mathias
- Subjects
- *
ACUTE myeloid leukemia treatment , *ACUTE myeloid leukemia diagnosis , *SORAFENIB , *AGE factors in disease , *PLACEBOS , *RANDOMIZED controlled trials , *ANTINEOPLASTIC antibiotics , *DAUNOMYCIN , *THERAPEUTIC use of antimetabolites , *CYTARABINE , *AGE distribution , *ANTINEOPLASTIC agents , *COMBINED modality therapy , *COMPARATIVE studies , *HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *TIME , *UREA , *VITAMIN B complex , *DISEASE relapse , *EVALUATION research , *ACUTE myeloid leukemia , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *BLIND experiment , *DISEASE progression , *KAPLAN-Meier estimator , *PROTEIN kinase inhibitors , *VITAMIN therapy , *THERAPEUTICS - Abstract
Background: Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid leukaemia. We investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger.Methods: This randomised, double-blind, placebo-controlled, phase 2 trial was done at 25 sites in Germany. We enrolled patients aged 18-60 years with newly diagnosed, previously untreated acute myeloid leukaemia who had a WHO clinical performance score 0-2, adequate renal and liver function, no cardiac comorbidities, and no recent trauma or operation. Patients were randomly assigned (1:1) to receive two cycles of induction therapy with daunorubicin (60 mg/m(2) on days 3-5) plus cytarabine (100 mg/m(2) on days 1-7), followed by three cycles of high-dose cytarabine consolidation therapy (3 g/m(2) twice daily on days 1, 3, and 5) plus either sorafenib (400 mg twice daily) or placebo on days 10-19 of induction cycles 1 and 2, from day 8 of each consolidation, and as maintenance for 12 months. Allogeneic stem-cell transplantation was scheduled for all intermediate-risk patients with a sibling donor and for all high-risk patients with a matched donor in first remission. Computer-generated randomisation was done in blocks. The primary endpoint was event-free survival, with an event defined as either primary treatment failure or relapse or death, assessed in all randomised patients who received at least one dose of study treatment. We report the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00893373, and the EU Clinical Trials Register (2008-004968-40).Findings: Between March 27, 2009, and Nov 28, 2011, 276 patients were enrolled and randomised, of whom nine did not receive study medication. 267 patients were included in the primary analysis (placebo, n=133; sorafenib, n=134). With a median follow-up of 36 months (IQR 35·5-38·1), median event-free survival was 9 months (95% CI 4-15) in the placebo group versus 21 months (9-32) in the sorafenib group, corresponding to a 3-year event-free survival of 22% (95% CI 13-32) in the placebo group versus 40% (29-51) in the sorafenib group (hazard ratio [HR] 0·64, 95% CI; 0·45-0·91; p=0·013). The most common grade 3-4 adverse events in both groups were fever (71 [53%] in the placebo group vs 73 [54%] in the sorafenib group), infections (55 [41%] vs 46 [34%]), pneumonia (21 [16%] vs 20 [14%]), and pain (13 [10%] vs 15 [11%]). Grade 3 or worse adverse events that were significantly more common in the sorafenib group than the placebo group were fever (relative risk [RR] 1·54, 95% CI 1·04-2·28), diarrhoea (RR 7·89, 2·94-25·2), bleeding (RR 3·75, 1·5-10·0), cardiac events (RR 3·46, 1·15-11·8), hand-foot-skin reaction (only in sorafenib group), and rash (RR 4·06, 1·25-15·7).Interpretation: In patients with acute myeloid leukaemia aged 60 years or younger, the addition of sorafenib to standard chemotherapy has antileukaemic efficacy but also increased toxicity. Our findings suggest that kinase inhibitors could be a useful addition to curative treatment for acute myeloid leukaemia. Overall survival after long-term follow-up and strategies to reduce toxicity are needed to determine the future role of sorafenib in treatment of this disease.Funding: Bayer HealthCare. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
28. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
- Author
-
Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, and Maertens, Johan
- Subjects
- *
TREATMENT effectiveness , *ACUTE myeloid leukemia , *CYTARABINE , *CLINICAL trials , *KINASES - Abstract
Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of polo-like kinases. Eighty-seven patients (median age 75 years) received LDAC 20 mg twice daily subcutaneously days 1-10 or LDAC + volasertib 350 mg IV days 1 + 15 every 4 weeks. Response rate (complete remission and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib vs LDAC (31.0% vs 13.3%; odds ratio, 2.91; P = .052). Responses in the LDAC + volasertib arm were observed across all genetic groups, including 5 of 14 patients with adverse cytogenetics. Median event-free survival was significantly prolonged by LDAC + volasertib compared with LDAC (5.6 vs 2.3 months; hazard ratio, 0.57; 95% confidence interval, 0.35-0.92; P = .021); median overall survival was 8.0 vs 5.2 months, respectively (hazard ratio, 0.63; 95% confidence interval, 0.40-1.00; P = .047). LDAC + volasertib led to an increased frequency of adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events; there was no increase in the death rate at days 60 + 90. This study was registered at www.clinicaltrials.gov as #NCT00804856. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
- Author
-
Placke, Theresa, Faber, Katrin, Nonami, Atsushi, Putwain, Sarah L., Salih, Helmut R., Heidel, Florian H., Krämer, Alwin, Root, David E., Barbie, David A., Krivtsov, Andrei V., Armstrong, Scott A., Hahn, William C., Huntly, Brian J., Sykes, Stephen M., Milsom, Michael D., Scholl, Claudia, and Fröhling, Stefan
- Subjects
- *
METHYLTRANSFERASES , *HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *LEUKEMIA etiology , *CELL cycle - Abstract
Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise to an aggressive subtype of acute myeloid leukemia (AML). Insights into MLL fusionmediated leukemogenesis have not yet translated into better therapies because MLL is difficult to target directly, and the identity of the genes downstream of MLL whose altered transcription mediates leukemic transformation are poorly annotated. We used a functional genetic approach to uncover that AML cells driven by MLL-AF9 are exceptionally reliant on the cell-cycle regulator CDK6, but not its functional homolog CDK4, and that the preferential growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid differentiation. CDK6 essentiality is also evident in AML cells harboring alternate MLL fusions and a mouse model of MLL AF9 driven leukemia and can be ascribed to transcriptional activation of CDK6 by mutant MLL. Importantly, the context-dependent effects of lowering CDK6 expression are closely phenocopied by a small-molecule CDK6 inhibitor currently in clinical development. These data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged AML, and underscore that cell-cycle regulators may have distinct, noncanonical, and nonredundant functions in different contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.